Get the Stockscreener App
10.94
2.84%
-0.32
Certara Inc stock is traded at $10.94, with a volume of 1.49M.
It is down -2.84% in the last 24 hours and down -4.04% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
See More
Previous Close:
$11.26
Open:
$11.25
24h Volume:
1.49M
Relative Volume:
0.86
Market Cap:
$1.77B
Revenue:
$394.50M
Net Income/Loss:
$-2.63M
P/E Ratio:
-547.00
EPS:
-0.02
Net Cash Flow:
$70.29M
1W Performance:
+14.68%
1M Performance:
-4.04%
6M Performance:
-19.62%
1Y Performance:
-16.30%
1-Day Range:
$10.86
$11.38
1-Week Range:
$9.47
$11.62
52-Week Range:
$8.635
$15.69
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
10.94 | 1.55B | 394.50M | -2.63M | 70.29M | -0.02 |
|
VEEV
Veeva Systems Inc
|
282.13 | 46.19B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
60.87 | 9.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
66.58 | 10.89B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.05 | 7.86B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
34.59 | 5.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-08-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Certara signals full year 8–10% revenue growth outlook as AI and QSP momentum builds - MSN
Certara, Inc. (NASDAQ:CERT) Q2 2025 Earnings Call Transcript - Insider Monkey
Certara, Inc.'s (NASDAQ:CERT) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Yahoo Finance
Certara, Inc. Reports Strong Q2 2025 Earnings Growth - TipRanks
Certara, Inc. (CERT) Q2 Earnings Miss Estimates - MSN
Certara 2025 Q2 Earnings Narrows Losses, Reports 84.3% Reduction in Net Loss - AInvest
Navigator Holdings Ltd. shares fall 1.00% intraday after Certara, Inc. reports Q2 2025 earnings. - AInvest
Certara, Inc. (CERT): A Bull Case Theory - Insider Monkey
UBS Maintains Certara (CERT) Rating, Lowers Price Target to $15. - GuruFocus
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns By Investing.com - Investing.com South Africa
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns - Investing.com Nigeria
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips - Investing.com
Certara's Q2 Results and Strategic Positioning Support Buy Rating with $16 Price Target - AInvest
Certara, Inc. Reports Strong Q2 2025 Growth - TipRanks
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara's AI-Driven Biosimulation Platform: A Catalyst for Drug Development Transformation - AInvest
Certara's Q2 2025 Earnings: Strategic Resilience in a Shifting Biosimulation Landscape - AInvest
Certara's Q2 2025 Earnings Call: Contradictory Signals on Market Potential, Demand Dynamics, and Retention Rates - AInvest
Certara Grows In Q2 But Falls Short Of Analyst Estimates - Finimize
Certara (CERT) Q2 Revenue Jumps 12% - The Globe and Mail
Certara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Press Release: Certara Reports Second Quarter 2025 Financial Results - 富途牛牛
Certara Q2 adjusted EPS misses estimates - MarketScreener
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss - Investing.com UK
CERT SEC FilingsCertara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Certara Reports Second Quarter 2025 Financial Results - The Globe and Mail
Visual analytics tools that track Certara Inc. performanceSwing Reversal Forecast Based on Patterns - Newser
Navigator Holdings Ltd. shares rise 1.84% intraday after Certara's Simcyp Simulator receives EMA qualification. - AInvest
The PBPK Revolution: How Certara's Simcyp Simulator is Reshaping Drug Development and Regulatory Acceptance - AInvest
Certara Simcyp Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - MarketScreener
Certara Obtains European Medicines Agency Qualification for Biosimulation Software - MarketScreener
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - The Manila Times
Certara's Simcyp® Simulator Achieves EMA Qualification for Regulatory Submissions in the EU - Quiver Quantitative
Breakthrough: Certara's Simcyp Becomes Only Software Qualified by EMA for Drug Interaction Studies - Stock Titan
Why is Certara Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
What institutional investors are buying Certara Inc. stockUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Certara Inc. expanding into Is KREF stock a good long term investment optionExceptional profit potential - Jammu Links News
What are analysts’ price targets for Certara Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is the risk reward ratio of investing in Certara Inc. stockNavigate market volatility with smart strategies - Jammu Links News
How strong is Certara Inc. company’s balance sheetFree Expert Stock Watchlist - Jammu Links News
What catalysts could drive Certara Inc. stock higher in 2025Dynamic growth stocks - Jammu Links News
What makes Certara Inc. stock price move sharplyBuild a portfolio that stands the test of time - Jammu Links News
Is Certara Inc. stock overvalued or undervaluedHigh-profit trading signals - Jammu Links News
What drives Certara Inc. stock priceBuild wealth steadily with smart stock selection - Jammu Links News
How many analysts rate Certara Inc. as a “Buy”Discover breakthrough trading strategies - Jammu Links News
Is Certara Inc. a good long term investmentUnmatched profit potential - Jammu Links News
How volatile is Certara Inc. stock compared to the marketAccess high-quality stock research instantly - Jammu Links News
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Enhance AI in Drug Development - AInvest
Certara names Christopher Bouton as chief technology officer By Investing.com - Investing.com South Africa
Certara names Christopher Bouton as chief technology officer - Investing.com
How Christopher Bouton's Leadership Is Reshaping Certara's AI-Driven Drug Development and Unlocking Shareholder Value - AInvest
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.97%
6.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):